Takashi Suzuki

发表

Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A

K. Amano, K. Fukutake, H. Inaba, 2013, International journal of hematology.

Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia

M. Nojima, T. Matsushita, K. Amano, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification of Missense Mutations in the FVII Gene of Three FVII Deficiencies

K. Amano, K. Fukutake, H. Inaba, 2001 .

Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency

K. Amano, K. Fukutake, H. Inaba, 2007 .

A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

A. Ishiguro, K. Yoneyama, K. Nogami, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model

V. Jiménez‐Yuste, E. Santagostino, R. Klamroth, 2020, Haematologica.

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

K. Nogami, M. Taki, K. Amano, 2022, BMJ Open.

Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.

F. Germini, Takashi Suzuki, A. Nagao, 2019, Thrombosis research.

Development of asymptomatic acquired factor V inhibitor after the administration of antibiotics.

Kazuaki Yoshimura, K. Shinozawa, Takashi Suzuki, 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology.

The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors

E. Ishii, Masao Kobayashi, A. Shirahata, 2015, International Journal of Hematology.

Hemostatic Management with Prothrombin Complex Concentrate in a Patient with Factor VII Deficiency Undergoing Resection of a Large Ovarian Cyst

K. Fukutake, K. Isaka, A. Sasaki, 2000 .

Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

J. Oldenburg, E. Santagostino, S. Zupančić šalek, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

A. Ishiguro, K. Yoneyama, K. Nogami, 2018, Blood.

Investigation of diffusion, practical use, and utility of a medical device for Japanese hemophilia patients in a single institution

Y. Okamoto, Takashi Suzuki, A. Nagao, 2019, Personalized Medicine Universe.

Clinical conditions and risk factors for inhibitor‐development in patients with haemophilia: A decade‐long prospective cohort study in Japan, J‐HIS2 (Japan Hemophilia Inhibitor Study 2)

J. Takamatsu, S. Ohga, Masao Kobayashi, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

D. Quon, J. Staber, B. Konkle, 2018, Blood.

Safety and efficacy of B-domain truncated recombinant factor VIII in previously treated patients with hemophilia A: Comparison of data between total population and Japanese subject population

Y. Sakata, T. Matsushita, K. Nogami, 2014 .

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A

J. Oldenburg, M. Ozelo, D. Quon, 2022, Human gene therapy.

Discrepancies between the one-stage clotting assay and chromogenic assay in patients with hemophilia A receiving standard or extended half-life factor VIII products in clinical settings.

M. Nojima, K. Suzuki-Inoue, M. Kaneko, 2019, Thrombosis research.

Autoantibody to factor VIII that has less reactivity to factor Vlll/von Willebrand Factor Complex

K. Amano, K. Fukutake, Takashi Suzuki, 1995, American journal of hematology.

The Prevalence of Co-infection with Hepatitis Viruses in Human Immunodeficiency Virus (HIV) Infected Patients in Japan and the Efficacy of Hepatitis B Virus (HBV) /Hepatitis A Virus (HAV) Vaccination

K. Amano, K. Fukutake, M. Ohtaki, 2007 .

Two double heterozygous mutations in the F7 gene show different manifestations

K. Amano, K. Fukutake, Y. Hatta, 2002, British journal of haematology.

Features of factor VIII activity measurement in Arg531His mutant detected in patients with mild hemophilia A

Y. Yatomi, K. Amano, K. Fukutake, 2008 .

The blood coagulation factor IX inhibitor

Takashi Suzuki, 2012 .

Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency

K. Amano, K. Fukutake, H. Inaba, 2014, International Journal of Hematology.

[Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjögren syndrome].

K. Fukutake, K. Ohyashiki, Y. Kimura, 2011, [Rinsho ketsueki] The Japanese journal of clinical hematology.

Two cases of acquired factor V inhibitor which were initially diagnosed with congenital deficiency by cross mixing tests

K. Amano, K. Fukutake, H. Inaba, 2018 .

Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency.

K. Amano, K. Fukutake, H. Inaba, 2007, International journal of hematology.

ANALYSIS OF DISCREPANT ASSAY-DETERMINED ACTIVITY LEVELS OF FACTOR VIII ASSOCIATED WITH R531H MUTATION

Y. Yatomi, K. Amano, K. Fukutake, 2007 .